The Effect of Onosma bracteatum in cancer cells
Jawaher Albaqami, Lewis Myles E, Venkataswarup Tiriveedhi, William Yaw Boadi, Nicole Driggins S · MOJ Bioequivalence & Bioavailability · 2018
Background: One significant cause of mortality and morbidity among populations around the globe is cancer. Many plants have shown their ability for use in developing anti-cancer drugs. Approximately 60% of all anti-cancer drugs, recently in use, are a compound derived from plants.1 Several studies have shown that extracted plants are capable of inducing apoptosis, reducing the lipid peroxides in various cancer cells. Herein, we examined the underlying mechanism of Onosma bracteatum cytotoxicity in prostate cancer (PC3), lung cancer (A549), and breast cancer (BT549). Methods: In this study, O. bracteatum leaves in methanol extract was prepared and exposed to a human breast, prostate, and lung cancer cells. Lipid peroxidation and Elisa assays were used to assess the cytotoxic effect of the O. bracteatum on BT549, PC3, and A549 cancer cells Result: We found that O. bracteatum with multiple concentrations (0.055, 0.11, 0.22, 0.44, 0,88, 1.7, and 3.52 µg/ml) reduced cell viability in a dose- and time-dependent method. The results from lipid peroxides assay indicate that the lipid peroxides (MDA) were decreased in prostate, breast, and lung cancer cells in concentration 1.76µg/ml, compared with the control group. Furthermore, Elisa assay also revealed that caspase-3 activated in prostate, breast, and lung cancer cells in concentration 1.76µg/ml compared to the control (DMSO). Conclusion: O. bracteatum has potential as a drug candidate for the treatment of prostate cancer, lung cancer, and breast cancer.